id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-327246-idmo5ds7	M, Montero-Baladía	Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients: Etoposide for severe COVID-19 patients	2020-06-21		.txt	text/plain	1408	112	40	Current evidence suggests that systemic hyperinflammation and immune dysregulation play a key role in the development of severe lung and multiorgan damage found in critically ill COVID-19 patients 2, 3, 4 . Patients eligible for etoposide treatment were older than 18 years, presented biochemical alterations suggestive of severe hyperinflammation (ferritin levels >1000 ng/ml and/or IL-6 values >50 pg/ml), ARDS (defined by PaO 2 /FiO 2 < 300) and were not under mechanical ventilation. These preliminary results on 11 patients confirmed the safety and efficacy of etoposide as adjunctive salvage treatment for critically ill COVID-19 ARDS patients, exhibiting systemic hyperinflammation and previously treated with corticosteroids and interleukin inhibitors. In this preliminary experience, salvage treatment with etoposide in adjunction to immunosuppressants resulted in overall favorable outcome of a small cohort of severely ill COVID-19 ARDS patients presenting with systemic hyperinflammation.	./cache/cord-327246-idmo5ds7.txt	./txt/cord-327246-idmo5ds7.txt